First Berlin Equity Research Adjusts Formycon Price Target
First Berlin Equity Research has lowered its price target for Formycon AG from 50 Euro to 46 Euro while maintaining a 'Buy' recommendation.
Stocks · News reference
Berenberg Research has updated its price target for Formycon AG while reaffirming a 'Buy' investment rating for the company.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
First Berlin Equity Research has lowered its price target for Formycon AG from 50 Euro to 46 Euro while maintaining a 'Buy' recommendation.
Formycon AG has officially named the reference drugs for its pipeline candidates FYB210 and FYB286, identifying them as Tezspire (tezepelumab) and Hemlibra (emicizumab), respectively.
Formycon AG announced its financial results for the first nine months of 2026, highlighting a significant revenue increase and key regulatory milestones for its biosimilar pipeline.
Formycon AG's ustekinumab biosimilar, Otulfi, has been approved for the treatment of moderate to severe Crohn's disease, plaque psoriasis, and psoriatic arthritis in Brazil.
Formycon AG is recognizing non-cash impairments on its FYB201 and FYB202 biosimilar products and has revised its adjusted EBITDA guidance for fiscal year 2026 due to increased market competition.
Formycon AG has scheduled the publication of its nine-month results for 2026 on November 12, 2026, and will host a corresponding conference call.